Prostate Cancer - Results from #840

Da Vinci vs. Hugo RAS for robot-assisted radical prostatectomy: a prospective comparative single-center study. May 22, 2024

Prognostic outcomes in Japanese patients with metastatic castration-sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor. May 22, 2024

Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study. May 22, 2024

Metabolic reprogramming of tumor-associated macrophages using glutamine antagonist JHU083 drives tumor immunity in myeloid-rich prostate and bladder cancer tumors. May 22, 2024

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial. May 21, 2024

Beyond PI-RADS: Combining MRI PI-RADS and PSMA-PET/CT PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer. May 21, 2024

AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer. May 21, 2024

Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. May 21, 2024

SpaceOAR Complication Affecting the Treatment of Prostate Cancer. May 21, 2024

Characterising the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases. May 21, 2024

Prostate Risk and Monitoring During Testosterone Replacement Therapy. May 20, 2024

A Model-Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk. May 20, 2024

Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates. May 20, 2024

Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer. May 20, 2024

Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer. May 20, 2024

Variation in content discussed by specialty in consultations for clinically localized prostate cancer. May 20, 2024

Development and Validation of a Survey to Assess Sexual Health in Female Partners of Patients with Prostate Cancer. May 20, 2024

Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer. May 17, 2024

Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol. May 17, 2024

PSMA-Targeted Radiopharmaceuticals for Prostate Cancer Diagnosis and Therapy. May 17, 2024

Page 43 of 1435